VERAXA Biotech (NASDAQ: VRXA) announced an expansion of its intellectual property portfolio, filing new patent applications during the first half of 2026 covering its next-generation BiTAC-TCE and BiTAC-ADC technology platforms and related therapeutic programs. The company said previously granted patents protecting supporting technologies have also cleared the opposition period, bringing its portfolio to more than 50 granted owned or exclusively licensed patents across 14 countries and 26 patent families. Pending approval of the latest filings, VERAXA expects its core technologies to be protected through at least 2047.
The company said its BiTAC platform is designed to improve the selectivity and safety of cancer therapies by activating treatments only when multiple tumor-associated targets are present. VERAXA also highlighted proprietary click chemistry, conjugation, linker and payload technologies intended to enhance the safety, efficacy and manufacturability of its antibody-drug conjugate and T-cell engager pipelines, reinforcing its long-term strategy to develop next-generation oncology therapeutics.
This patent expansion is significant because it strengthens VERAXA's competitive position in the rapidly evolving field of cancer immunotherapy. By securing intellectual property around its BiTAC platform and related technologies, the company aims to differentiate its therapies from traditional bispecific antibodies and ADCs, which often suffer from off-target toxicity. The ability to protect these innovations through at least 2047 provides a long runway for commercialization and potential partnerships.
For investors and industry observers, the breadth and depth of VERAXA's patent portfolio signal a commitment to building a robust pipeline. The company's focus on selectivity and safety addresses key challenges in oncology, where treatments must balance efficacy with minimizing harm to healthy cells. The BiTAC platform's dual-targeting mechanism could lead to therapies with fewer side effects, potentially improving patient outcomes and adherence.
VERAXA's technology originated from scientific breakthroughs at the European Molecular Biology Laboratory (EMBL), a world-renowned institution. The company has translated this research into a suite of transformative technologies, including bispecific T-cell engagers and bispecific ADCs. As the oncology landscape shifts toward more targeted and personalized approaches, VERAXA's patented innovations could play a crucial role in shaping next-generation standards of care.
The full press release is available at https://ibn.fm/BqhFS. For the latest news and updates relating to VRXA, visit the company’s newsroom at https://ibn.fm/VRXA.
Forward-looking statements in this article involve risks and uncertainties, including those detailed in the company's SEC filings. Undue reliance should not be placed on these statements, which are based on information available as of the date hereof. All parties undertake no duty to update this information unless required by law.
